[go: up one dir, main page]

WO2005116659A3 - Compositions and methods relating to alzheimer’s disease - Google Patents

Compositions and methods relating to alzheimer’s disease Download PDF

Info

Publication number
WO2005116659A3
WO2005116659A3 PCT/US2005/017263 US2005017263W WO2005116659A3 WO 2005116659 A3 WO2005116659 A3 WO 2005116659A3 US 2005017263 W US2005017263 W US 2005017263W WO 2005116659 A3 WO2005116659 A3 WO 2005116659A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
compositions
alzheimer
methods relating
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/017263
Other languages
French (fr)
Other versions
WO2005116659A2 (en
Inventor
David Lowe
Howard Schulman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEURODX LLC
Original Assignee
NEURODX LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEURODX LLC filed Critical NEURODX LLC
Publication of WO2005116659A2 publication Critical patent/WO2005116659A2/en
Publication of WO2005116659A3 publication Critical patent/WO2005116659A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions, kits, and methods for diagnosing, characterizing, and treating Alzheimer’s Disease (AD) are disclosed. Polypeptides and non-peptide small molecules, which were identified as differentially expressed in samples obtained from AD subjects as compared to samples obtained from non-AD subjects can be used as polypeptide markers and metabolite markers, respectively. The markers can be used alone or in combination.
PCT/US2005/017263 2004-05-18 2005-05-18 Compositions and methods relating to alzheimer’s disease Ceased WO2005116659A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57225804P 2004-05-18 2004-05-18
US60/572,258 2004-05-18

Publications (2)

Publication Number Publication Date
WO2005116659A2 WO2005116659A2 (en) 2005-12-08
WO2005116659A3 true WO2005116659A3 (en) 2006-09-08

Family

ID=34975179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/017263 Ceased WO2005116659A2 (en) 2004-05-18 2005-05-18 Compositions and methods relating to alzheimer’s disease

Country Status (1)

Country Link
WO (1) WO2005116659A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013273746A1 (en) * 2006-02-28 2014-02-20 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
ATE535535T1 (en) * 2006-02-28 2011-12-15 Phenomenome Discoveries Inc METHODS FOR DIAGNOSING DEMENTIA AND OTHER NEUROLOGICAL DISEASES
WO2008095275A1 (en) 2007-02-08 2008-08-14 Phenomenome Discoveries Inc. Methods for the treatment of senile dementia of the alzheimer's type
CN113049696B (en) * 2021-03-04 2022-03-18 首都医科大学宣武医院 Metabolite for diagnosing whether subject suffers from Alzheimer disease and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414336A (en) * 1981-01-28 1983-11-08 The Green Cross Corporation Method for preparing sample for use in endotoxin test
US20020104104A1 (en) * 1995-06-07 2002-08-01 Kate Dora Games Method for identifying alzheimer's disease therapeutics using transgenic animal models

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414336A (en) * 1981-01-28 1983-11-08 The Green Cross Corporation Method for preparing sample for use in endotoxin test
US20020104104A1 (en) * 1995-06-07 2002-08-01 Kate Dora Games Method for identifying alzheimer's disease therapeutics using transgenic animal models

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAKINO T: "Use of microtiter plates for latex agglutination immunoassay of serum alpha 2-macroglobulin.", ANNALS OF CLINICAL AND LABORATORY SCIENCE. APR 2001, vol. 31, no. 2, April 2001 (2001-04-01), pages 205 - 210, XP008053348, ISSN: 0091-7370 *
VAN GOOL D ET AL: "alpha 2-Macroglobulin expression in neuritic-type plaques in patients with Alzheimer's disease.", NEUROBIOLOGY OF AGING. 1993 MAY-JUN, vol. 14, no. 3, May 1993 (1993-05-01), pages 233 - 237, XP002347247, ISSN: 0197-4580 *
ZHANG RULIN ET AL: "Mining biomarkers in human sera using proteomic tools.", PROTEOMICS. JAN 2004, vol. 4, no. 1, January 2004 (2004-01-01), pages 244 - 256, XP008034741, ISSN: 1615-9853 *

Also Published As

Publication number Publication date
WO2005116659A2 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
CA2602088C (en) Biomarkers for ovarian cancer and endometrial cancer
WO2007062090A3 (en) Methods and compositions related to b cell assays
WO2007076439A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
WO2007086904A3 (en) Compositions for use in identification of adenoviruses
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
ATE512365T1 (en) MAP-2 PROTEOLYTIC PRODUCTS AS DIAGNOSTIC BIOMARKERS FOR NEURAL INJURY
UA96139C2 (en) Anti-neuropilin-1 (nrp1) antibody
WO2007103770A3 (en) Compositions and methods for analyzing renal cancer
WO2007011907A3 (en) Alpha-synuclein antibodies and methods related thereto
WO2007118222A3 (en) Compositions for the use in identification of fungi
WO2007084264A3 (en) Methods for myocardial imaging
WO2006134390A3 (en) Method for diagnosing neurodegenerative disease
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
DE602007011566D1 (en) Ankheit
WO2010021822A3 (en) Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
DK1866650T3 (en) Neurodegenerative markers of depression
WO2008089072A3 (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
WO2007028162A3 (en) Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
WO2008034016A3 (en) Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
WO2009020596A3 (en) Embryonic cerebrospinal fluis (e-csf), proteins from e-csf, and related methods and compositions
WO2007047408A3 (en) Promac signature application
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
WO2006079101A3 (en) Associations using genotypes and phenotypes
WO2006086242A3 (en) Mild osteoarthritis biomarkers and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO R69(1) EPC FORM 1205A OF 23-02-2007

122 Ep: pct application non-entry in european phase